

<Organisation Details>
<Organisation Address>
<Organisation Details>
<Today's date>

<Patient Name>
<Patient Address>

Dear <Patient Name>

DOB: <Date of Birth> NHS No: <NHS number>

RE: Changes to your brand of rapid acting insulin to Trurapi

Our records show that you are using rapid acting insulin aspart (also known as Novorapid) to manage your diabetes.

The NHS now has another brand of insulin aspart available to prescribe called Trurapi.

Trurapi is a [biosimilar](#)* version of the insulin aspart contained in your current Novorapid pen (*this means it is exactly the same product as NovoRapid). It has been tested to ensure that it is equally effective and safe. Trurapi is the preferred insulin aspart product on the Dorset formulary, and local diabetes experts have agreed that patients who are currently being treated with Novorapid should be considered as appropriate to switch to Trurapi.

We have therefore switched your insulin from: Novorapid® Flexpen Prefilled Pens to Trurapi® SoloSTAR Prefilled Pens

There is no required change to your current dose.

Continue to monitor your glucose levels in your usual way.

If you have any concerns about your glucose levels, please contact your doctor or your usual diabetes team.

Trurapi is a SOLOSTAR device and will work the same as all other SOLOSTAR devices.

For more information regarding using your new insulin, please visit: <https://www.mysanofiinsulin.co.uk/trurapi/> If you don't have access to the internet, you can find instructions inside the packaging of your new Trurapi insulin.

If you have any questions about how to use the pen, then please contact your community pharmacy, GP practice or diabetes team.

Yours sincerely

<GP Name>
<Organisation Details>